Becton, Dickinson and (NYSE:BDX – Get Rating) had its price objective increased by Morgan Stanley from $290.00 to $295.00 in a research note issued to investors on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the medical instruments supplier's stock.
Several other equities analysts also recently weighed in on the stock. William Blair reissued an outperform rating on shares of Becton, Dickinson and in a research note on Friday, November 11th. Cowen reduced their price objective on Becton, Dickinson and to $255.00 in a research report on Wednesday, November 16th. Piper Sandler upped their target price on Becton, Dickinson and from $245.00 to $260.00 and gave the company a neutral rating in a report on Thursday. Evercore ISI reduced their price target on Becton, Dickinson and to $270.00 in a report on Wednesday, November 16th. Finally, Bank of America raised shares of Becton, Dickinson and from a neutral rating to a buy rating and upped their price objective for the company from $250.00 to $290.00 in a report on Tuesday, January 3rd. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $275.64.
Get Becton Dickinson and alerts:Becton, Dickinson and Stock Down 1.1 %
BDX stock opened at $245.84 on Friday. The stock has a market capitalization of $69.88 billion, a P/E ratio of 46.38, a P/E/G ratio of 2.13 and a beta of 0.54. Becton, Dickinson and has a 52 week low of $215.90 and a 52 week high of $280.62. The firm has a 50-day simple moving average of $251.67 and a 200-day simple moving average of $244.48. The company has a quick ratio of 0.63, a current ratio of 1.07 and a debt-to-equity ratio of 0.56.
Becton, Dickinson and (NYSE:BDX – Get Rating) last released its earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.30. Becton, Dickinson and had a return on equity of 13.52% and a net margin of 8.47%. The business had revenue of $4.59 billion for the quarter, compared to the consensus estimate of $4.59 billion. During the same quarter last year, the business posted $3.64 earnings per share. The business's quarterly revenue was down 2.8% compared to the same quarter last year. Equities analysts forecast that Becton, Dickinson and will post 12.2 earnings per share for the current fiscal year.Becton, Dickinson and Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be paid a $0.91 dividend. The ex-dividend date is Thursday, March 9th. This represents a $3.64 annualized dividend and a dividend yield of 1.48%. Becton, Dickinson and's dividend payout ratio (DPR) is 68.68%.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of BDX. Red Tortoise LLC acquired a new position in Becton, Dickinson and during the 4th quarter worth approximately $25,000. Legend Financial Advisors Inc. lifted its holdings in Becton, Dickinson and by 105.6% during the 4th quarter. Legend Financial Advisors Inc. now owns 111 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 57 shares during the last quarter. Trifecta Capital Advisors LLC acquired a new position in shares of Becton, Dickinson and during the 4th quarter worth about $31,000. Western Pacific Wealth Management LP purchased a new position in shares of Becton, Dickinson and in the 3rd quarter valued at about $30,000. Finally, Chilton Capital Management LLC purchased a new stake in Becton, Dickinson and during the second quarter worth approximately $39,000. 87.08% of the stock is currently owned by hedge funds and other institutional investors.
Becton, Dickinson and Company Profile
(Get Rating)
Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.
See Also
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.